Generation of induced pluripotent stem cells (iPSCs) via the ectopic expression of reprogramming factors is a simple, advanced, yet often inefficient, slow, stochastic technology due to the overexpression of multiple genes. Scientists of Creative Biolabs have used almost all available approaches for the delivery of reprogramming factors. Creative Biolabs has developed streamed-line protocols for efficient iPSC generation with viral vectors, DNA (plasmid), RNA and recombinant proteins. Each of these services will be provided with a comprehensive report suitable for publications.
In 2006, Yamanaka’s team first produced iPSCs from mouse embryonic fibroblasts (MEFs) by introducing four factors Oct4, Sox2, KLF4, and c-myc. iPSCs have similar pluripotency and self-renewal capacity to embryonic stem cells (ESCs). When establishing a method for efficiently generating and differentiating iPSCs, regenerative medicine with transplantation of iPSCs-derived cells, tissues, or organs will approach reality. One advantage of using autografts from patient-derived iPSCs is that the risk of immune rejection is very low. iPSCs can be generated from various types of cells with transduction of defined transcription factors.
Generation of iPS Cells from Hematopoietic Cells
Due to the high reprogramming efficiency, hematopoietic cells can be obtained in a minimally invasive way and will be a good donor source for establishing iPSCs. Various methods for establishing iPSCs from hematopoietic cells have been reported.
- Generation of iPS cells from B lymphocyte
- Generation of iPS cells from hematopoietic stem/progenitor cells obtained from peripheral blood or umbilical cord blood
- Generation of iPS cells from peripheral T lymphocytes and myeloid cells
Generation of iPS Cells from Hematological Malignancy
iPSCs can be generated not only from normal cells but also from several types of tumor cells. Disease-specific iPSCs, especially from hematological malignancies, are useful because primary samples of hematological malignancies are usually difficult to be expanded. After the establishment of iPSCs with malignant cell genome abnormalities, iPSCs with genetic abnormalities can be distinguished and continuously obtained. They will be used in studies that require large numbers of living cells, proteomes, epigenome and transcriptome profiling, leukemia stem cell analysis or drug screening assays. iPSCs from hematological malignancies have been established from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.
